Sorafenib Inhibits Tumor Growth and Improves Survival in a Transgenic Mouse Model of Pancreatic Islet Cell Tumors

Background. The purpose of the study was to evaluate Sorafenib (BAY 43-9006) derived receptor tyrosine kinase inhibition on tumor progression in murine islet cell tumors. Sorafenib is considered to be a potent inhibitor of tumor angiogenesis and neovascularization in various solid tumors. Rip1Tag2 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Fendrich, Volker, Maschuw, Katja, Rehm, Johannes, Buchholz, Malte, Holler, Julia P., Slater, Emily P., Bartsch, Detlef K., Waldmann, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Scientific World Journal 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543792/
https://www.ncbi.nlm.nih.gov/pubmed/23346016
http://dx.doi.org/10.1100/2012/529151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543792/
https://www.ncbi.nlm.nih.gov/pubmed/23346016
http://dx.doi.org/10.1100/2012/529151

Ejemplares similares